Since our founding in 2003, we have pursued our vision of using the immune system to find and fight proteins central to the development and progression of chronic human diseases. Our ultimate aim is to improve the lives of patients suffering from chronic diseases, by focusing on the root cause rather than symptom management: an ethos inspired by the impact that vaccines have on health and society worldwide. Our portfolio of immunotherapy candidates which are currently in clinical trials or in preclinical development for a variety of chronic diseases include hypercholesterolemia and Huntington’s disease (mutHTT).
Meet our exceptional team, who have a proven track record of making ground-breaking scientific discoveries and developing novel therapies.
Together we can achieve more.
Claus is a serial entrepreneur in the Life Sciences with 20 years’ experience in the Industry. In 2001, he cofounded Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and executed the listing of the Company at NASDAQ as CFO, playing a key role in transforming Pieris from a biotech Start-up to a mature biopharmaceutical company.
Claus also cofounded XL-protein GmbH and led the Company to profitability through a series of collaborations with Pharma and Biotech. Claus also supports other biotech companies in part-time management positions. He holds a Master degree in Business Administration from the University of Bamberg, Germany.
Dr. Barrett was CEO of AFFiRiS AG for a three year period up to April 2022. During this period he was instrumental in managing the sale of the alpha-synuclein and beta-amyloid neurodegenerative disease assets to AC Immune. He also managed the resulting restructuring process , the establishment of the AFFiRiS CVD GmbH company spin- off and the negotiation of the co-development partnership for the cardiovascular PCSK9 program with Frontier Biotechnologies.